136 related articles for article (PubMed ID: 32233172)
21.
Lepak AJ; Zhao M; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036691
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.
Ferrari L; Iavarone L; Braggio S; Di Modugno E
Antimicrob Agents Chemother; 2003 Feb; 47(2):770-6. PubMed ID: 12543690
[TBL] [Abstract][Full Text] [Related]
23. Best alternative to vancomycin for serious methicillin-resistant Staphylococcus aureus infections: let's just say it.
Bush LM
Clin Infect Dis; 2011 Nov; 53(9):965-6. PubMed ID: 21880584
[No Abstract] [Full Text] [Related]
24. Efficacy and quality of antibacterial generic products approved for human use: a systematic review.
Tattevin P; Crémieux AC; Rabaud C; Gauzit R
Clin Infect Dis; 2014 Feb; 58(4):458-69. PubMed ID: 24265357
[TBL] [Abstract][Full Text] [Related]
25. In vivo inferiority of generic product compared with branded vancomycin: a paradigm shift.
Jong GW
Ther Drug Monit; 2012 Feb; 34(1):2-3. PubMed ID: 22210101
[No Abstract] [Full Text] [Related]
26. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
Wicha WW; Craig WA; Andes D
J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
[TBL] [Abstract][Full Text] [Related]
27. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Gonzalez JM; Rodriguez CA; Zuluaga AF; Agudelo M; Vesga O
PLoS One; 2015; 10(11):e0141872. PubMed ID: 26536105
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
29. Considerations about the Use of a Loading Dose of Daptomycin in a Neutropenic Murine Thigh Infection Model with Methicillin-Resistant Staphylococcus aureus Infection.
Kato H; Hagihara M; Murakami E; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Uno B; Mikamo H
Chemotherapy; 2018; 63(1):13-19. PubMed ID: 29130946
[TBL] [Abstract][Full Text] [Related]
30. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Ghosh N; Chavada R; Maley M; van Hal SJ
Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
[TBL] [Abstract][Full Text] [Related]
31. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
Placencia FX; Kong L; Weisman LE
Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
[TBL] [Abstract][Full Text] [Related]
32. Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
Hsu AJ; Hamdy RF; Huang Y; Olson JA; Ghobrial S; Gerber JS; Hersh AL; Tamma PD
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):338-341. PubMed ID: 28992126
[TBL] [Abstract][Full Text] [Related]
33. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model.
Zuluaga AF; Agudelo M; Cardeño JJ; Rodriguez CA; Vesga O
PLoS One; 2010 May; 5(5):e10744. PubMed ID: 20505762
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
Hamada Y; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
[TBL] [Abstract][Full Text] [Related]
35. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection.
Wang J; Shan Q; Ding H; Liang C; Zeng Z
Antimicrob Agents Chemother; 2014 Jun; 58(6):3008-12. PubMed ID: 24614373
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
39. Methicillin-resistant Staphylococcus aureus pneumonia treatment: do not confuse pharmacokinetics and pharmacodynamics.
Moine P; Bédos JP
Chest; 2007 Sep; 132(3):1101, author reply 1102-3. PubMed ID: 17873216
[No Abstract] [Full Text] [Related]
40. [Persistent bacteremia due to methicillin-resistant Staphylococcus aureus. A result of inadequate treatment].
Parra-Ruiz J; Tomas-Jiménez C; Muñoz-Medina L; Hernández-Quero J
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):372-3. PubMed ID: 19339080
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
